High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women are some of the key drivers contributing to the robust growth of the menopausal hot flashes treatment market. Hence, healthcare companies are increasing their clinical trials in non-hormonal products to meet various cases. Recently, in January 2020, the U.K.-based clinical-stage biotech company KaNDy Therapeutics, announced positive data of their Phase 2b “SWITCH-1” clinical trial of their novel lead non-hormonal drug candidate, NT-814, for the treatment of menopause. Though the hormonal treatment type segment is expected to lead the menopausal hot flashes treatment market, non-hormonal treatment type segment is anticipated for exponential growth during the forecast period.
Companies in the market for menopausal hot flashes are increasing R&D in treatment options that target the brain’s thermostat to reduce incidence of hot flashes in women. Such innovations are creating value-grab opportunities for companies in the market menopausal hot flashes treatment market, whilst improving the quality of life of postmenopausal women.
The menopausal hot flashes treatment market is expected to grow at a CAGR of 6% during the forecast period. Most women from Generation X are now in their 40s and are technologically proficient. Likewise, online drug sales is anticipated to flourish in the market for menopausal hot flashes. However, there is a lack of interest from the femtech toward solving the issues of women’s midlife health issues.
The femtech sector has been more active toward solving the issues of menstrual health and pregnancy. However, there is a growing need for attention toward women’s midlife health issues such as menopausal hot flashes. Hence, companies are exploring untapped opportunities to address the stigma and associated silence pertaining to symptoms of menopause.
Companies in the menopausal hot flashes treatment market are targeting digitally literate women to create awareness about the issues related to menopause through social media. They are increasing their efficacy in complementary and alternative medicine (CAM) for management of hot flashes.
Apart from innovations in medicines, companies in the menopausal hot flashes treatment market are recommending women toward lifestyle modifications through online media channels. Likewise, companies are developing cutting-edge devices that suit the needs of women. For instance, the introduction of the Menopod™ has led to the growth of market for menopausal hot flashes, owing to its compact computer mouse-like shape and portability. The advent of smartwatch-like devices that act as a personal thermostat for women is also driving the global market.
Due to high prevalence of tech-savvy women in their late 40s, companies in the market for menopausal hot flashes are unearthing value opportunities with the development of mobile apps. These mobile apps are providing healthcare companies with important insights about the frequency of hot flashes in women. On the other hand, companies in the menopausal hot flashes treatment market are increasing research in customizable mattresses that offer cooling and heating temperature controls.
The demand for nonpharmacologic treatment options is projected to escalate in the menopausal hot flashes treatment market. Thus, healthcare providers are adopting cognitive behavior therapy to improve menopause symptoms. This novel therapy is being highly publicized for not only treating hot flashes, but is also effective for other menopause symptoms. Companies in the menopausal hot flashes treatment market are creating awareness about cognitive behavior therapy, owing to its advantages of modifying dysfunctional emotions, behaviors and thoughts that enhance personal coping strategies. Since researchers have gained clinical success with the help of cognitive behavior therapy for the treatment of anxiety and depression, healthcare companies are expanding their healthcare services using the novel therapy.
Complications associated with menopausal hot flashes such as sleep disturbances and low-productivity levels in professional environments are increasing the demand for cognitive behavior therapy among patients. Long-term effectiveness of cognitive behavior therapy post treatment are creating lucrative opportunities for healthcare providers. Thus, healthcare companies are increasing efforts to conduct large-scale clinical trials in order to analyze its effectiveness in highly symptomatic women.
Analysts’ Viewpoint
Apart from innovations in medicines, alternative options such as weight-training and lifestyle modifications are proving to be effective for hot flashes. The hormone replacement therapy is highly popular in the menopausal hot flashes treatment market. However, controversies encircling the risk of blood clots, stroke, and some cancers pose a barrier for market growth. Hence, companies should tap opportunities in alternative treatment options such as cognitive behavior therapy, which is not only effective in the management of hot flashes, but also treats other symptoms such as anxiety and sleep disorders. Digitalization of health is another key driver contributing toward market growth, as femtech can target tech-savvy women through social media and innovative mobile apps.
Menopausal hot flashes treatment market is expected to grow at a CAGR of 6% during 2019 - 2027
Menopausal hot flashes treatment market is driven by growing awareness about women's health on the back of public as well as private initiatives
North America accounted for a major share of the global menopausal hot flashes treatment market
Key players in the menopausal hot flashes market include Pfizer Inc., Allergan plc, Novo Nordisk A/S, Novartis AG, TherapeuticsMD, Inc., GlaxoSmithKline plc, Merck & Co., Inc., and Mylan N.V.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Menopausal Hot Flashes Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Mergers, Acquisitions and Strategic Partnerships
5.3. Value Chain Analysis
6. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2017–2027
6.3.1. Hormonal Treatment
6.3.1.1. Estrogen
6.3.1.2. Progesterone
6.3.1.3. Estrogen-Progesterone Combination
6.3.2. Non-Hormonal Treatment
6.3.2.1. Antidepressant
6.3.2.1.1. Paroxetine
6.3.2.1.2. Fluoxetine
6.3.2.1.3. Venlafaxine
6.3.2.1.4. Desvenlafaxine
6.3.2.1.5. Others
6.3.2.2. Gabapentin
6.3.2.3. Progabalin
6.3.2.4. Clonidine
6.3.3. Alternative Treatment
6.3.3.1. Black Cohosh
6.3.3.2. Vitamin E
6.3.3.3. Herbal Medicines
6.3.3.4. Others
6.4. Market Attractiveness By Product Type, 2019-2027
7. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness By Distribution Channel, 2019-2027
8. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region, 2019-2027
9. North America Menopausal Hot Flashes Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Product Type, 2017–2027
9.2.1. Hormonal Treatment
9.2.1.1. Estrogen
9.2.1.2. Progesterone
9.2.1.3. Estrogen-Progesterone Combination
9.2.2. Non-Hormonal Treatment
9.2.2.1. Antidepressant
9.2.2.1.1. Paroxetine
9.2.2.1.2. Fluoxetine
9.2.2.1.3. Venlafaxine
9.2.2.1.4. Desvenlafaxine
9.2.2.1.5. Others
9.2.2.2. Gabapentin
9.2.2.3. Progabalin
9.2.2.4. Clonidine
9.2.3. Alternative Treatment
9.2.3.1. Black Cohosh
9.2.3.2. Vitamin E
9.2.3.3. Herbal Medicines
9.2.3.4. Others
9.3. Market Value Forecast By Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast By Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis, 2019-2027
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Menopausal Hot Flashes Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product Type, 2017–2027
10.2.1. Hormonal Treatment
10.2.1.1. Estrogen
10.2.1.2. Progesterone
10.2.1.3. Estrogen-Progesterone Combination
10.2.2. Non-Hormonal Treatment
10.2.2.1. Antidepressant
10.2.2.1.1. Paroxetine
10.2.2.1.2. Fluoxetine
10.2.2.1.3. Venlafaxine
10.2.2.1.4. Desvenlafaxine
10.2.2.1.5. Others
10.2.2.2. Gabapentin
10.2.2.3. Progabalin
10.2.2.4. Clonidine
10.2.3. Alternative Treatment
10.2.3.1. Black Cohosh
10.2.3.2. Vitamin E
10.2.3.3. Herbal Medicines
10.2.3.4. Others
10.3. Market Value Forecast By Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast By Country, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis, 2019-2027
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country
11. Asia Pacific Menopausal Hot Flashes Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product Type, 2017–2027
11.2.1. Hormonal Treatment
11.2.1.1. Estrogen
11.2.1.2. Progesterone
11.2.1.3. Estrogen-Progesterone Combination
11.2.2. Non-Hormonal Treatment
11.2.2.1. Antidepressant
11.2.2.1.1. Paroxetine
11.2.2.1.2. Fluoxetine
11.2.2.1.3. Venlafaxine
11.2.2.1.4. Desvenlafaxine
11.2.2.1.5. Others
11.2.2.2. Gabapentin
11.2.2.3. Progabalin
11.2.2.4. Clonidine
11.2.3. Alternative Treatment
11.2.3.1. Black Cohosh
11.2.3.2. Vitamin E
11.2.3.3. Herbal Medicines
11.2.3.4. Others
11.3. Market Value Forecast By Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast By Country, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis, 2019-2027
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country
12. Latin America Menopausal Hot Flashes Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product Type, 2017–2027
12.2.1. Hormonal Treatment
12.2.1.1. Estrogen
12.2.1.2. Progesterone
12.2.1.3. Estrogen-Progesterone Combination
12.2.2. Non-Hormonal Treatment
12.2.2.1. Antidepressant
12.2.2.1.1. Paroxetine
12.2.2.1.2. Fluoxetine
12.2.2.1.3. Venlafaxine
12.2.2.1.4. Desvenlafaxine
12.2.2.1.5. Others
12.2.2.2. Gabapentin
12.2.2.3. Progabalin
12.2.2.4. Clonidine
12.2.3. Alternative Treatment
12.2.3.1. Black Cohosh
12.2.3.2. Vitamin E
12.2.3.3. Herbal Medicines
12.2.3.4. Others
12.3. Market Value Forecast By Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast by Country, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis, 2019-2027
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country
13. Middle East & Africa Menopausal Hot Flashes Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2017–2027
13.2.1. Hormonal Treatment
13.2.1.1. Estrogen
13.2.1.2. Progesterone
13.2.1.3. Estrogen-Progesterone Combination
13.2.2. Non-Hormonal Treatment
13.2.2.1. Antidepressant
13.2.2.1.1. Paroxetine
13.2.2.1.2. Fluoxetine
13.2.2.1.3. Venlafaxine
13.2.2.1.4. Desvenlafaxine
13.2.2.1.5. Others
13.2.2.2. Gabapentin
13.2.2.3. Progabalin
13.2.2.4. Clonidine
13.2.3. Alternative Treatment
13.2.3.1. Black Cohosh
13.2.3.2. Vitamin E
13.2.3.3. Herbal Medicines
13.2.3.4. Others
13.3. Market Value Forecast By Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast By Country, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis, 2019-2027
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share/Position Analysis By Company (2018)
14.3. Company Profiles
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Novartis AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Novo Nordisk A/S
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Allergan plc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Mylan N.V.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Hisamitsu Pharmaceutical Co., Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. GlaxoSmithKline plc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. TherapeuticsMD, Inc.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, by Phase II, Phase I, and Preclinical
Table 03: Key Mergers, Acquisitions, and Strategic Partnerships
Table 04: Global Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 05: Global Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 06: Global Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 07: Global Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressant, 2017–2027
Table 08: Global Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 09: Global Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Global Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 11: North America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 12: North America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 13: North America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 14: North America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 15: North America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressant, 2017–2027
Table 16: North America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 17: North America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 18: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 20: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 21: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 22: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressants, 2017–2027
Table 23: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 24: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 25: Asia Pacific Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 26: Asia Pacific Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 27: Asia Pacific Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 28: Asia Pacific Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 29: Asia Pacific Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressant, 2017–2027
Table 30: Asia Pacific Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 31: Asia Pacific Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Latin America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 33: Latin America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 34: Latin America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 35: Latin America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 36: Latin America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressant, 2017–2027
Table 37: Latin America Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 38: Latin America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 39: Middle East & Africa Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 40: Middle East & Africa Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 41: Middle East & Africa Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Hormonal Treatment, 2017–2027
Table 42: Middle East & Africa Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Non-hormonal Treatment, 2017–2027
Table 43: Middle East & Africa Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Non-hormonal Treatment – Antidepressant, 2017–2027
Table 44: Middle East & Africa Menopausal Hot Flashes Treatment Market Size (US$ Mn) Forecast, by Treatment Type – Alternative Treatment, 2017–2027
Table 45: Middle East & Africa Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Menopausal Hot Flashes Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Menopausal Hot Flashes Treatment Market Value (US$ Mn) Analysis, 2017–2027
Figure 03: Global Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type (2018)
Figure 04: Global Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel (2018)
Figure 05: Global Menopausal Hot Flashes Treatment Market Value Share, by Region (2018)
Figure 06: Global Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment (2018)
Figure 07: Global Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment (2018)
Figure 08: Global Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment (2018)
Figure 09: Global Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant (2018)
Figure 10: Global Menopausal Hot Flashes Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 11: Global Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 12: Global Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 13: Global Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 14: Global Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 15: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y (%) Analysis, by Hormonal Treatment, 2017–2027
Figure 16: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y (%) Analysis, by Non-hormonal Treatment, 2017–2027
Figure 17: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y (%) Analysis, by Alternative Treatment, 2017–2027
Figure 18: Global Menopausal Hot Flashes Treatment Market Attractiveness Analysis, by Treatment Type, 2019–2027
Figure 19: Global Menopausal Hot Flashes Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 20: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 21: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 22: Global Menopausal Hot Flashes Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 23: Global Menopausal Hot Flashes Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 24: Global Menopausal Hot Flashes Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 25: Global Menopausal Hot Flashes Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 26: North America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 27: North America Menopausal Hot Flashes Treatment Market Value Share, by Country, 2018 and 2027
Figure 28: North America Menopausal Hot Flashes Treatment Market Attractiveness, by Country, 2019–2027
Figure 29: North America Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 30: North America Menopausal Hot Flashes Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 31: North America Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 32: North America Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 33: North America Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 34: North America Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 35: North America Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 36: North America Menopausal Hot Flashes Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 37: Europe Menopausal Hot Flashes Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), 2017–2027
Figure 38: Europe Menopausal Hot Flashes Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 39: Europe Menopausal Hot Flashes Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 40: Europe Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 41: Europe Menopausal Hot Flashes Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 42: Europe Menopause Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 43: Europe Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 44: Europe Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 45: Europe Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 46: Europe Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 47: Europe Menopausal Hot Flashes Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 48: Asia Pacific Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 49: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 50: Asia Pacific Menopausal Hot Flashes Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 51: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 52: Asia Pacific Menopausal Hot Flashes Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 53: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 54: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 55: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 56: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 57: Asia Pacific Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 58: Asia Pacific Menopausal Hot Flashes Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 59: Latin America Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 60: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 61: Latin America Menopausal Hot Flashes Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 62: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 63: Latin America Menopausal Hot Flashes Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 64: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 65: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 66: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 67: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 68: Latin America Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 69: Latin America Menopausal Hot Flashes Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 70: Middle East & Africa Menopausal Hot Flashes Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 71: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 72: Middle East & Africa Menopausal Hot Flashes Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 73: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 74: Middle East & Africa Menopausal Hot Flashes Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 75: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Hormonal Treatment, 2018 and 2027
Figure 76: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Non-hormonal Treatment, 2018 and 2027
Figure 77: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Alternative Treatment, 2018 and 2027
Figure 78: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Antidepressant, 2018 and 2027
Figure 79: Middle East & Africa Menopausal Hot Flashes Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 80: Middle East & Africa Menopausal Hot Flashes Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 81: Market Position Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Menopausal Hot Flashes Treatment Market
